



# Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer

## SUPPLEMENTARY FIGURES AND TABLES



Analytic size exclusion HPLC analyses performed on a Superose 12 column, 10/300 GL, 11  $\mu\text{m}$  (GE Healthcare), isocratic elution (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid HEPES, 150 mM NaCl, pH = 7.3, flow rate: 0.5 mL.min<sup>-1</sup>)

Supplementary Figure 1: HPLC analyses of radiolabeled of  $[^{111}\text{In}]\text{DOTA-Ts29.2}$  (left) and  $[^{177}\text{Lu}]\text{DOTA-Ts29.2}$  (right).



**Supplementary Figure 2:** **A.** CT images (left: sagittal, right: axial) of mice used for volume organs determination involved in S factors calculation. The arrows indicate the tumors. **B.** mRNA quantification of TSPAN8 in different cell lines according to the tissue type. These data were extracted from the study of Klijn C. *et al.* [35]. Red crosses represent the mean, box plots encompass the median value (central line), and crosses that do not enter in the boxes can be considered as extreme values.

Supplementary Tables 1 and 2: Dosimetry calculations performed by computing S factors with the GATE Monte Carlo platform and biodistribution data

<sup>177</sup> Lu S-factors		targets							
Gy/Bq/s		rest of body	tumor	spleen	kidneys	liver	heart	lungs	brain
<b>sources</b>	<i>rest of body</i>	<b>6.06E-13</b>	3.13E-14	8.62E-14	3.85E-14	5.00E-14	4.91E-14	5.80E-14	3.82E-14
	<i>tumor</i>	3.65E-14	<b>3.21E-11</b>	1.54E-17	1.88E-17	6.06E-17	5.16E-17	2.02E-16	1.97E-17
	<i>spleen</i>	1.01E-13	1.52E-17	<b>1.62E-10</b>	6.18E-14	2.65E-15	2.67E-17	4.64E-17	5.21E-18
	<i>kidneys</i>	4.52E-14	1.80E-17	6.72E-14	<b>3.95E-11</b>	3.23E-14	1.89E-17	2.96E-17	3.45E-18
	<i>liver</i>	5.80E-14	5.94E-17	2.61E-15	3.41E-14	<b>1.47E-11</b>	5.18E-15	8.45E-14	7.17E-18
	<i>heart</i>	4.89E-14	5.95E-17	2.47E-17	1.70E-17	1.22E-14	<b>4.66E-11</b>	3.80E-12	1.79E-17
	<i>lungs</i>	6.74E-14	2.04E-16	4.64E-17	2.91E-17	8.44E-14	9.84E-13	<b>3.78E-11</b>	1.85E-17
	<i>brain</i>	4.43E-14	1.97E-17	5.09E-18	3.30E-18	7.89E-18	2.19E-17	1.89E-17	<b>5.21E-11</b>

<sup>90</sup> Y S-factors		targets							
Gy/Bq/s		rest of body	tumor	spleen	kidneys	liver	heart	lungs	brain
<b>sources</b>	<i>rest of body</i>	<b>4.71E-12</b>	5.37E-13	2.91E-12	2.41E-12	2.18E-12	1.80E-12	2.40E-12	1.75E-12
	<i>tumor</i>	1.42E-12	<b>8.51E-11</b>	5.24E-16	1.61E-14	3.48E-12	2.04E-15	2.39E-12	2.81E-16
	<i>spleen</i>	3.35E-12	2.11E-16	<b>5.50E-11</b>	3.88E-11	3.00E-13	3.56E-16	5.17E-16	8.57E-17
	<i>kidneys</i>	3.85E-12	2.68E-16	7.92E-13	<b>7.52E-11</b>	1.14E-13	2.80E-16	3.86E-16	7.35E-17
	<i>liver</i>	3.01E-12	4.52E-15	1.91E-12	2.36E-11	<b>2.64E-11</b>	7.45E-14	2.07E-13	1.26E-16
	<i>heart</i>	1.41E-12	1.34E-15	9.11E-16	6.16E-16	3.51E-11	<b>1.15E-10</b>	1.63E-11	2.77E-16
	<i>lungs</i>	1.89E-12	2.69E-13	1.79E-12	1.08E-10	4.10E-11	1.22E-11	<b>4.17E-11</b>	2.54E-16
	<i>brain</i>	3.82E-12	1.80E-15	1.76E-16	1.32E-16	2.92E-16	1.29E-15	9.44E-16	<b>1.01E-10</b>

Dose values (Gy) were calculated for a 3.7 MBq injection of the radiolabeled antibody Ts29.2. Ratios of doses between tumor and other organs were evaluated